A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2014

At a glance

  • Drugs JNJ 54861911 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 13 Jan 2014 According to ClinicalTrials.gov, the status changed from active no longer recruiting to completed.
    • 27 Aug 2013 Planned number of patients changed from 40 to 62 as reported by ClinicalTrials.gov.
    • 27 Aug 2013 Planned End Date changed from 1 Aug 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top